DELHI, India, Dec. 08, 2020 (GLOBE NEWSWIRE) -- "Bevacizumab Biosimilar Market Opportunity, Sales, Price & Clinical Trials Insight 2025" Report Highlights:
- Bevacizumab Market Opportunity: > USD 12 Billion by 2025
- Bevacizumab Biosimilar in Clinical Trials: > 25 Biosimilars
- Bevacizumab Biosimilar Available in Market: >8 Biosimilars
- Bevacizumab Market Spread: US & Europe Share > 60%
- Bevacizumab Branded v/s Biosimilar Insight
- Avastin & Bevacizumab Biosimilar Price, Sales & Dosage Insight
- Bevacizumab Patent Insight by Indication & Year
Download Report (120 Page Publication): https://www.kuickresearch.com/report-bevacizumab-biosimilar-market-sales-size-forecast-bevacizumab-biosimilars-mvasi-zirabev-avastin-bevacizumab--biosimilar-clinical-trials
Available biologic and branded top-selling cancer drugs are set to get declined as a biosimilar drug Bevacizumab is set to overcome all the challenges associated with old and traditional cancer therapy market and to take the number-one position in the global cancer therapeutics industry. The analyzed continuous regulatory wins by the biosimilar drug is poised to make the Fierce Pharma’s Bevacizumab as the best biosimilar selling drug in the next few years. The wide-spread applications of the drug in over-coming the current challenges in the cancer therapeutics industry is inclined towards making the drug the king-of-the-hill in the future global drug sales. The emergence of the biosimilar drug having equal opportunities as the branded drug is set to provide a high revenue stream that will chip away the highest market share in the entire biosimilar drug market and cancer therapeutics market.
The biosimilar drug market for bevacizumab is observed to rack up hundreds of regulatory approvals for different cancer indications, proving that the research and clinical activities associated with the drug is promising and prominent. In a short period of time, the drug has become one of the fundamental cancer treatments. Approved against different cancer indications alone or in combination with other cancer therapies have changed the way of treatment regimen and the perception of the patients towards biosimilars in providing ample amount of healthcare benefits to the cancer patients across the globe.
The predictions for the sales of the drug in the future shows that the drug in a very short period of time will occupy top position. The growing trends and opportunities associated with the biosimilar drug is not bound to get affected by the branded drugs as the researchers and the government sector are now more aligned towards extending the market so that maximum patients could respond to the therapy. At regional level, the segmentation of the market in major developed markets of the world such as North America, Europe and Latin America is also making the bevacizumanb biosimilar drug as one of the largest contributors to the global biosimilar market and cancer therapeutics market.
As per the research conducted for Global Bevacizumab biosimilar drug, it is estimated that the drug has been playing a very humongous and dynamic role in causing a decline in the overall cancer mortality rate as a greater number of patients are now able to consume the drugs. At global level, the emergence of the biosimilar drug against different types of cancer indications has refreshed the entire cancer therapeutics market in terms of delivering standard and cheap cancer treatment. The current potential of the market is reflecting top-notch performance for the cancer patients and a market that is anticipated towards huge growth rate and robust sales. In addition to this, it is estimated that market is now bound to sweep away all the challenges that were present in the cancer market for long period of time, thus inclining the entire biosimilar market towards dominating the other commercially available therapies.
Table of Contents (120 Page Report)
1. Bevacizumab - Current Market Overview
2. Bevacizumab - Reimbursement Scenario
3. Bevacizumab - Commercial Availability
4. Bevacizumab Biosimilar Market Analysis
4.1 Current Market Scenario
4.2 Market Opportunities & Forecast
5. Global Bevacizumab Biosimilar Ongoing Clinical Trials Outlook
5.1 Country
5.2 Indication
5.3 Patient Segment
5.4 Organization
6. Global Bevacizumab Biosimilar Clinical Insight By Phase
6.1 Unknown
6.2 Research
6.3 Preclinical
6.4 Clinical
6.5 Phase-I
6.6 Phase-II
6.7 Phase-II/III
6.8 Phase-III
6.9 Preregistration
6.10 Registered
7. Marketed Bevacizumab Branded & Biosimilar Drug Clinical Insight
7.1 Avastin
7.2 Bevacizumab Biosimilar - KRABEVA
7.3 Bevacizumab Biosimilar - BYVASDA
7.4 Bevacizumab Biosimilar - Bevax
7.5 Bevacizumab Biosimilar - ZIRABEV
7.6 Bevacizumab Biosimilar - Mvasi
7.7 Bevacizumab Biosimilar - Bryxta
7.8 Bevacizumab Biosimilar Bevatas
7.9 Bevacizumab Biosimilar - Cizumab
7.10 Bevacizumab Biosimilar - Versavo
7.11 Bevacizumab Biosimilar - Lumiere
8. Bevacizumab Biosimilar Market - Future Outlook
9. Competitive Landscape
9.1 Amgen
9.2 AryoGen Pharmed
9.3 Biothera
9.4 Boehringer Ingelheim
9.5 Centus Biotherapeutics
9.6 Henlius Biotech
9.7 Innovent Biologics
9.8 Mylan
9.9 mAbxience
9.10 Outlook Therapeutics
9.11 Pfizer
9.12 Prestige Biopharma
9.13 Roche
9.14 Samsung Bio
9.15 TOT Biopharm
Contact:
Neeraj Chawla
neeraj@kuickresearch.com
+91-9810410366